Topic: non-Hodgkin lymphoma
Chinese authorities have approved Fosun subsidiary Henlius' Rituxan copycat, the country's first biosimilar.
Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that.
All eyes are on Roche as the first biosimilar rival to big-selling lymphoma blockbuster Rituxan won FDA approval.
The first dual PI3K-delta/gamma inhibitor will go up against Gilead's Zydelig, the first PI3K inhibitor, and Bayer’s Aliqopa.
Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.
England's cost-effectiveness watchdogs gave Novartis the go-ahead for its CAR-T drug, Kymriah, to treat leukemia.
Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.
Kyowa is also testing the drug in early-phase trials for solid tumors, in combo with its own IDO inhibitor KHK2455, BMS’ Opdivo and AZ’s Imfinzi.
Celgene ended a losing streak Monday with a Revlimid trial win, and one analyst thinks more rosy pipeline events could follow soon.